ECM
AQST icon

ExodusPoint Capital Management’s Aquestive Therapeutics AQST Stock Holding History

ExodusPoint Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38,103
Closed -$213K – 1519
2025
Q3 		$213K Buy
+38,103
New +$165K ﹤0.01% 1375
2025
Q2 		– Sell
-189,177
Closed -$549K – 1447
2025
Q1 		$549K Buy
189,177
+116,670
+161% +$353K 0.01% 1088
2024
Q4 		$258K Buy
72,507
+24,984
+53% +$115K ﹤0.01% 1318
2024
Q3 		$237K Buy
+47,523
New +$185K ﹤0.01% 1421
2024
Q2 		– Sell
-52,168
Closed -$222K – 1509
2024
Q1 		$222K Buy
52,168
+26,089
+100% +$86.8K ﹤0.01% 1326
2023
Q4 		$53K Buy
+26,079
New +$46.1K ﹤0.01% 1380
2022
Q2 		– Sell
-11,140
Closed -$29K – 1913
2022
Q1 		$29K Sell
11,140
-13,335
-54% -$38.9K ﹤0.01% 2092
2021
Q4 		$95K Buy
+24,475
New +$123K ﹤0.01% 1961
2021
Q3 		– Sell
-13,399
Closed -$53K – 2084
2021
Q2 		$53K Buy
+13,399
New +$53.5K ﹤0.01% 2215
2020
Q4 		– Sell
-26,808
Closed -$130K – 1939
2020
Q3 		$130K Buy
+26,808
New +$175K ﹤0.01% 1559

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ExodusPoint Capital Management's AQST Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Aquestive Therapeutics (AQST) in Q4 2025, closing a stake of 38,103 shares — an estimated $213K sold.

ExodusPoint Capital Management first reported a position in AQST in Q3 2020 and held it in 10 quarters. The position peaked at $549K in Q1 2025. 176 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Aquestive Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 38,103 Aquestive Therapeutics shares in Q4 2025, an estimated $213K.
  • ExodusPoint Capital Management first reported a position in Aquestive Therapeutics in Q3 2020 and held it in 10 quarters.
  • ExodusPoint Capital Management's Aquestive Therapeutics position peaked at $549K in Q1 2025.
  • 176 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.